Knight Reports Fourth Quarter and Year-Ended December 31, 2015 Results
MONTREAL, CANADA–(Marketwired – Mar 24, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight” or the “Company”), a leading Canadian specialty pharmaceutical company, today reported financial results for its fourth quarter and year-ended December 31, 2015. 2015 Highlights Knight secured the rights to over 20 innovative pharmaceutical products, consumer health products and medical devices, in various stages […]
Knight Receives Dividend From Medison
MONTREAL, CANADA–(Marketwired – Mar 23, 2016) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today receipt of a NIS 7.1 million [$2.4 million] dividend from Medison Biotech (1995) Ltd. (“Medison”). Knight owns 28.3% of Medison, Israels 4th largest specialty pharma company ranked by revenue. “Six months into our strategic collaboration […]
Knight Obtains Impavido Worldwide Rights
MONTREAL, QUEBEC–(Marketwired – Mar 15, 2016) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today that it now owns worldwide rights to Impavido® (miltefosine) as a result of the termination of its agreement with Paladin Labs (Barbados) Inc., (an affiliate of Endo International plc) related to the distribution and sale […]
Knight Breaks Glass on Medimetriks Partnership
MONTREAL, CANADA and NEW JERSEY, UNITED STATES–(Marketwired – Feb 17, 2016) – Knight Therapeutics Inc. (TSX:GUD) (Knight) and Medimetriks Pharmaceuticals, Inc. (Medimetriks) announced today that Knight has agreed to issue a secured loan of up to US$20 million to support Medimetriks’ acquisition of the exclusive U.S. development and commercialization rights for OPA-15406 from Otsuka Pharmaceutical […]
INTEGA Skin Looks GUD to Knight
MONTREAL, QUEBEC–(Marketwired – Jan 25, 2016) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that it has entered into a secured loan agreement with INTEGA Skin Sciences Inc. (“INTEGA”), a new Montreal-based skincare company aspiring to become a benchmark in the pharmaceutical industry in the treatment and care of […]
Knight Loan to Extenway Impaired
MONTREAL, CANADA–(Marketwired – Dec 22, 2015) – Extenway Solutions Inc. (“Extenway”) announced yesterday that a receiver was appointed over the majority of its assets under direction from Caisse Desjardins de Beauport, another secured creditor. Knight Therapeutics Inc. (TSX:GUD) (“Knight”) entered into a secured loan of $800,000 with Extenway in June 2015 which is currently outstanding. […]
Knight Takes Right Angle With 60 Degrees Pharmaceuticals LLC
MONTREAL, CANADA–(Marketwired – Dec 11, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today that it has extended the first tranche of a fully secured loan of up to US$4 Million to 60° Pharmaceuticals LLC (“60P”). The loan proceeds will allow 60P to continue the development of medicines for […]
CRH Makes GUD on Knight Secured Loan
MONTREAL, CANADA–(Marketwired – Nov 25, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced that later today it will successfully exit its investment in CRH Medical Corporation (TSX:CRH)(NYSE:CRHM) (“CRH”) following early repayment of the remaining balance of US$22.0 million on its secured loan to CRH. In December of 2014, Knight […]
Knight to Present at the TD Securities Technology & Healthcare Conference in Toronto
MONTREAL, CANADA–(Marketwired – Nov 17, 2015) – Knight Therapeutics Inc. (TSX:GUD) (“Knight”), a leading Canadian specialty pharmaceutical company, announced today that Jonathan Ross Goodman, President & CEO, is scheduled to present a corporate update at the TD Securities Technology & Healthcare Conference on Friday, November 20, 2015 at 10:00 am ET at the St. Andrew’s […]
Knight Partner FOCUSed on Growth
MONTREAL, CANADA–(Marketwired – Nov 16, 2015) – Knight Therapeutics Inc. (TSX:GUD), through one of its wholly-owned subsidiaries (“Knight”), announced today that it has agreed to extend an additional secured loan of US$5.5 million to Synergy CHC Corp. (OTCQB:SNYR) (“Synergy”). The secured loan will support Synergy’s acquisition of Flat Tummy Tea and UrgentRx™, two established brands […]
